European Journal of Heart Failure最新文献

{"title":"Impact of dapagliflozin, spironolactone and their combination on markers of kidney function and injury: an analysis from SOGALDI-PEF.","authors":"João Pedro Ferreira,Joana Mascarenhas,Pedro Marques,Luís Mendonça,Abhinav Sharma,Faiez Zannad,Jorge S Almeida,Ricardo Fontes-Carvalho,Joana Pimenta,Adelino Leite-Moreira,Francisco Vasques-Nóvoa, ","doi":"10.1093/ejhf/xuag117","DOIUrl":"https://doi.org/10.1093/ejhf/xuag117","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"8 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Alternative Path in Transthyretin Amyloid Cardiomyopathy.","authors":"Anne Sophie O Olesen,Nicolas Girerd,Pardeep S Jhund","doi":"10.1093/ejhf/xuag118","DOIUrl":"https://doi.org/10.1093/ejhf/xuag118","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"2 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary Mitral and Tricuspid Regurgitation in Early HFrEF: The Impact of Contemporary Medical Therapy.","authors":"Anne Sophie O Olesen,Marco Metra,Pardeep S Jhund","doi":"10.1093/ejhf/xuag115","DOIUrl":"https://doi.org/10.1093/ejhf/xuag115","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"63 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart Failure in Pregnancy: Where the 2025 ESC Guidelines \"Cardiovascular disease and pregnancy\" Illuminate-and Where Shadows Remain.","authors":"Amina Rakisheva,Karen Sliwa,Johann Bauersachs,Mark C Petrie,Peter van Der Meer,Insa Emrich","doi":"10.1093/ejhf/xuag124","DOIUrl":"https://doi.org/10.1093/ejhf/xuag124","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"55 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Kidney Failure Risk Equation and Risk of Kidney and Cardiovascular Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Insights from PARADIGM-HF.","authors":"Iris E Beldhuis,Brian L Claggett,Brendon L Neuen,Safia Chatur,Navdeep Tangri,Finnian R Mc Causland,Adriaan A Voors,Jean L Rouleau,Michael R Zile,Karl Swedberg,Akshay S Desai,Martin P Lefkowitz,Milton Packer,John J V McMurray,Scott D Solomon,Muthiah Vaduganathan","doi":"10.1093/ejhf/xuag079","DOIUrl":"https://doi.org/10.1093/ejhf/xuag079","url":null,"abstract":"BACKGROUND AND AIMSThe use of the Kidney Failure Risk Equation (KFRE) is guideline recommended in patients with chronic kidney disease (CKD) to predict risk of kidney failure, however, this has not been well studied in patients with heart failure (HF).METHODSThe KFRE score incorporates baseline urine albumin-creatinine ratio (UACR), age, sex, and estimated glomerular filtration rate (eGFR). Among patients with HF and reduced EF (HFrEF) and CKD in PARADIGM-HF, we explored the association of the 2- and 5-year KFRE score continuously, risk-based categories, and in quartiles with subsequent cardiovascular and kidney outcomes.RESULTSAmong 794 patients with HFrEF and eGFR<60 ml/min/1.73m2 with all KFRE variables available, median 5-year KFRE score was 0.63% [0.28%-1.67%]. Patients with higher KFRE baseline score had higher systolic blood pressure and NT-proBNP levels and were more likely to have a history of diabetes or atrial fibrillation, or to be treated with diuretics at baseline. The KFRE 5-year score was not significantly associated with the composite of ESKD or 50% decline in eGFR (HR 1.45; 95% CI 0.93-2.25; P=0.10), although confidence limits were wide in light of few events. Continuous KFRE 5-year score was associated with cardiovascular death or HF hospitalization (HR 1.22; 95% 1.09-1.36; P<0.001) and all-cause mortality (HR 1.24; 95% CI 1.10-1.39; P<0.001).CONCLUSIONSThese data suggest that the KFRE is associated with risk of cardiovascular events in patients with HFrEF. However, as the median KFRE was low in PARADIGM-HF, these data require validation in HF populations with more advanced CKD.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"135 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147648899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spironolactone, Early Acute eGFR Changes, and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from TOPCAT Americas.","authors":"Iris E Beldhuis,Brian L Claggett,Brendon L Neuen,Safia Chatur,Finnian R Mc Causland,Adriaan A Voors,Akshay S Desai,Eldrin F Lewis,Bertram Pitt,Marc A Pfeffer,Scott D Solomon,Muthiah Vaduganathan","doi":"10.1093/ejhf/xuag099","DOIUrl":"https://doi.org/10.1093/ejhf/xuag099","url":null,"abstract":"BACKGROUND AND AIMSEarly acute changes in estimated glomerular filtration rate (eGFR) have been well described with renin-angiotensin-system inhibitors and sodium-glucose cotransporter-2 inhibitors, but less is known about the frequency, prognostic relevance, and implications of these changes after mineralocorticoid receptor antagonist (MRA) initiation in patients with heart failure with preserved ejection fraction (HFpEF).METHODSWe performed a post-hoc analysis of 1,648 patients enrolled in the TOPCAT Americas region, defining an early eGFR dip as a ≥15% decrease in eGFR between baseline and week 4. Landmark analyses assessed the association of eGFR changes, treatment, and cardiovascular death, HF hospitalization, or aborted cardiac arrest.RESULTSWithin 4 weeks of treatment initiation, 431 (26%) patients experienced acute eGFR decrease with a higher proportion of patients assigned to spironolactone (269 [33%]) compared with placebo (162 [20%]) (OR 1.97; 95% CI 1.58-2.47). An acute eGFR decrease was independently associated with higher risk of subsequent cardiovascular outcomes, irrespective of treatment arm. However, treatment with spironolactone appeared beneficial in reducing the primary cardiovascular outcome irrespective of the presence (HR 0.75 [0.53-1.08]) or absence (0.80 [0.64-1.00]) of early eGFR decrease (pinteraction=0.81). At any given magnitude of eGFR decline, risk of the primary endpoint was consistently lower with spironolactone compared with placebo (pinteraction=0.64).CONCLUSIONSEarly acute eGFR changes were common and adversely prognostic in patients with HFpEF. Spironolactone treatment was beneficial in improving cardiovascular outcomes, despite a modest increase in the likelihood of acute eGFR decrease. An acute eGFR decrease early after MRA initiation should not automatically prompt treatment discontinuation.","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"23 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147648898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Heart Failure \"Nudges\" for Treatment Optimization in the Emergency Department: The Nudge HF study.","authors":"João Pedro Ferreira,Inês Pereira-Sousa,Sílvia O Diaz,Francisca Saraiva,Francisco Vasques-Nóvoa,Filipa Barbosa,Pedro Marques,Afonso Pedrosa,Jorge S Almeida,Adelino Leite-Moreira,Cristina Marujo","doi":"10.1093/ejhf/xuag123","DOIUrl":"https://doi.org/10.1093/ejhf/xuag123","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"11 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to 'The Illusion of Improvement in ATTR-CM: Re-evaluating Informative Missingness and Discordant Endpoints in ATTRibute-CM'.","authors":"Francesco Cappelli, Marianna Fontana, Pablo Garcia-Pavia, Daniel P Judge, Laura Obici, Ahmad Masri, Kai Vogtländer, Antonio Ciaccia, Ana Zazula, Jean-François Tamby, Adam Castaño, Steen H Poulsen, Thibaud Damy, James L Januzzi, Julian D Gillmore","doi":"10.1093/ejhf/xuag122","DOIUrl":"https://doi.org/10.1093/ejhf/xuag122","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.8,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147661919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Finerenone Across a Range of Heart Failure Duration: A Prespecified Analysis of the FINEARTS-HF Trial.","authors":"Yasuhiro Hamatani, John W Ostrominski, Henri Lu, Brian L Claggett, Zi Michael Miao, Akshay S Desai, Pardeep S Jhund, Alasdair D Henderson, Carolyn S P Lam, Michele Senni, Sanjiv J Shah, Adriaan A Voors, Faiez Zannad, Bertram Pitt, Maria Borentain, Andrea Scalise, James Lay-Flurrie, Katja Rohwedder, John J V McMurray, Scott D Solomon, Muthiah Vaduganathan","doi":"10.1093/ejhf/xuag119","DOIUrl":"https://doi.org/10.1093/ejhf/xuag119","url":null,"abstract":"<p><strong>Aims: </strong>Clinicians may be less inclined to consider new therapies in patients with long-standing heart failure (HF) due in part to clinical inertia. Whether the treatment effects of the non-steroidal mineralocorticoid receptor antagonist finerenone vary according to HF duration remains uncertain.</p><p><strong>Methods: </strong>In this prespecified analysis of the FINEARTS-HF trial, HF duration (defined as the time from diagnosis) was categorized into four groups: <3 months, ≥3 months to 2 years, ≥2 to 5 years, or ≥5 years. The primary outcome was a composite of cardiovascular death and total HF events. The efficacy and safety of finerenone were analyzed across the duration of HF.</p><p><strong>Results: </strong>Among 5,977 participants with available data (age: 72±10 years; 46% female), those with longer duration HF were older and had a higher comorbidity burden, while most patients, irrespective of HF duration, had NYHA class II functional status. Compared with HF duration <3 months, longer HF duration experienced a significantly higher adjusted risk of the primary outcome. The benefit of finerenone was consistent across HF duration categories: the rate ratio (95%CI) for the primary outcome in the <3-month group was 0.84 (0.61-1.16); ≥3 months to 2 years, 0.95 (0.74-1.23); ≥2 to 5 years, 0.77 (0.61-0.98); and ≥5 years, 0.81 (0.64-1.02) (Pinteraction=0.46). Drug discontinuation due to serious adverse events was similar between finerenone and placebo, regardless of HF duration.</p><p><strong>Conclusions: </strong>These findings suggest that even patients with long-standing HF with only mild functional status limitation may still benefit from further therapeutic optimization with therapies such as finerenone.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.8,"publicationDate":"2026-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147662010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From evidence to adoption: lessons from the OPTIPHARM-HF registry.","authors":"Stefan Störk,Birgit Aßmus","doi":"10.1093/ejhf/xuaf011","DOIUrl":"https://doi.org/10.1093/ejhf/xuaf011","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":"20 1","pages":""},"PeriodicalIF":18.2,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147641606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}